Organovo Announces Proposed Public Offering of Common Stock
October 19 2016 - 3:07PM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a
three-dimensional biology company focused on delivering scientific
and medical breakthroughs using its 3D bioprinting technology,
today announced that it has commenced an underwritten public
offering of its common stock. The offering is subject to
market and other conditions, and there can be no assurance as to
the completion, size and terms of the offering.
Jefferies LLC and Evercore ISI are acting as joint
book-running managers for the offering. Raymond James &
Associates, Inc. is acting as lead manager, and BTIG is acting as
co-manager.
The shares described above will be offered pursuant
to a shelf registration statement on Form S-3 previously filed with
and declared effective by the Securities and Exchange
Commission ("SEC"). Organovo intends to file a
preliminary prospectus supplement relating to the offering with
the SEC, which will be available, along with the accompanying
prospectus filed with the SEC in connection with the
shelf registration, on the SEC's website
at www.sec.gov. Copies of the preliminary prospectus
supplement and the accompanying prospectus may also be obtained by
sending a request to: Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 12th
Floor, New York, New York 10022, by telephone at 877-547-6340,
or by email at Prospectus_Department@Jefferies.com; or Evercore
Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd
Street, 36th Floor, New York, NY 10055 or by email at
ecm.prospectus@evercore.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy any securities of Organovo,
nor shall there be any sale of securities in any state or
jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. This press
release is being issued pursuant to and in accordance with Rule 134
under the Securities Act of 1933, as amended.
About Organovo Holdings,
Inc.Organovo designs and creates functional,
three-dimensional human tissues for use in medical research and
therapeutic applications. The Company develops 3D human
tissue models through internal development and in collaboration
with pharmaceutical, academic and other partners.
Organovo's 3D human tissues have the potential to accelerate
the drug discovery process, enabling treatments to be developed
faster and at lower cost. The Company’s ExVive Human Liver
and Kidney Tissues are used in toxicology and other preclinical
drug testing. The Company also actively conducts early
research on specific tissues for therapeutic use in direct surgical
applications. In addition to numerous scientific
publications, the Company’s technology has been featured
in The Wall Street Journal, Time Magazine, The Economist,
Forbes, and numerous other media outlets. Organovo is
changing the shape of life science research and transforming
medical care.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts constitute forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. The factors that could cause the Company's
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the ability to complete the proposed
offering; risks and uncertainties relating to the Company's ability
to develop, market and sell products and services based on its
technology; the expected benefits and efficacy of the Company's
products, services and technology; the market acceptance of the
Company's products and services; the Company's business, research,
product development, regulatory approval, marketing and
distribution plans and strategies; the Company's ability to
successfully complete the contracts and recognize the revenue
represented by the contracts included in its previously reported
total contract bookings and secure additional contracted
collaborative relationships; the final results of the Company's
preclinical studies may be different from the Company's studies or
interim preclinical data results and may not support further
clinical development of its therapeutic tissues; the Company may
not successfully complete the required preclinical and clinical
trials required to obtain regulatory approval for its therapeutic
tissues on a timely basis or at all; the risk of further
adjustments to the Company’s select preliminary financial results
for the second quarter of fiscal 2016; and the Company’s ability to
meet its fiscal year 2017 outlook and/or its long-range outlook.
These and other factors are identified and described in more detail
in the Company's filings with the SEC, including its Annual
Report on Form 10-K filed with the SEC on June 9,
2016, its Quarterly Report on Form 10-Q filed with the SEC on
August 4, 2016, its preliminary prospectus supplement to be filed
with the SEC on October 19, 2016, and its other filings filed with
the SEC. You should not place undue reliance on these
forward-looking statements, which speak only as of the date that
they were made. These cautionary statements should be
considered with any written or oral forward-looking statements that
the Company may issue in the future. Except as required by
applicable law, including the securities laws
of the United States, the Company does not intend to
update any of the forward-looking statements to conform these
statements to reflect actual results, later events or circumstances
or to reflect the occurrence of unanticipated events.
Investor Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Press Contact:
Jessica Yingling
Little Dog Communications
+1 (858) 344-8091
jessica@litldog.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Oct 2023 to Oct 2024